Clinical Validation of a Prognostic Tool in a Population of Outpatients Treated for Incurable Cancer Undergoing Anticancer Therapy: PRONOPALL Study.
H. Bourgeois,F. Grude,P. Solal-Celigny,O. Dupuis,E. Voog,G. Ganem,F. Denis,M. Zinger, L. Juhel-Voog,C. Lafond,P. Maillart,O. Capitain,R. Delva,P. Soulie,S. Abadie-Lacourtoisie,V. Guerin-Meyer, M. E. Morin-Meschin, J. M. Commer,A. Gangler, B. d'Aillieres,A. Zannetti,E. Bourbouloux, D. Berton-Rigault, S. Lebouvier-Sadot,M. Kaassis,J. Baudon, Y. H. Lam,A. Bizieux,M. Marcq,J. Edeline,F. Le Du, C. Lefeuvre,P. Deguiral,V. Delecroix,E. Blot,J. Egreteau,M. J. Goudier,R. Lamy,M. Ferec,X. Artignan,S. Corbinais,H. Morel,A. C. Hardy-Bessard,C. Alleaume, E. Naudeix,O. Cojocarasu,J. P. Metges,C. Riche,E. Gamelin,D. Deniel-Lagadec,F. Marhuenda,P. Ingrand,J. Y. Douillard Annals of Oncology（2017）
Key words
prognostic tool,palliative care,lactate dehydrogenase,serum albumin,Performance Status (PS ECOG),survival at 2 months
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper